Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high39.50 10/10/17
52 week low20.20 16/12/16
52 week change 8.13 (40.63%)
4 week volume5,172,806 18/11/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Allergy Therapeutics co-development agreement with Ergomed

Allergy Therapeutics has entered into a co-development collaboration agreement with Ergomed for the clinical developme...

Co-development agreement with Ergomed plc

RNS Number: 0248Z Allergy Therapeutics PLC 12 December 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics enters co-development agreement with Ergomed plc 12 December 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it h...

Holding(s) in Company

RNS Number: 7505Y Allergy Therapeutics PLC 07 December 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Allergy ...

All resolutions passed at AGM of Allergy Therapeutics

Allergy Therapeutics has announced that all resolutions were passed by shareholders at today's Annual General Meeting. A...

Result of AGM

RNS Number: 2447X Allergy Therapeutics PLC 22 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Result of Annual General Meeting 22 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that, at its Annual General Meeting held this m...

Block Listing Application

RNS Number: 0383X Allergy Therapeutics PLC 21 November 2017 21 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Block Listing Application Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that an application has been made to the London Stoc...

Allergy Therapeutics to Present at Jefferies 2017

RNS Number: 2495W Allergy Therapeutics PLC 13 November 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Allergy Therapeutics to Present at Jefferies 2017 London Healthcare Conference 13 November 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces th...

Director/PDMR Shareholding

RNS Number: 8138V Allergy Therapeutics PLC 07 November 2017 The announcement released by Allergy Therapeutics plcentitled "Director/ PDMR Shareholding" on 7 November 2017 at 11:54 incorrectly stated the exercise price as 0.0001 per share. The correct exercise price is 0.001. All other figures remain unchanged. The correct figure is included in the reissued ann...

Fundamental DataMore

EPS-0.42
Dividend yield0 %

Latest discussion posts More

  • co-development collaboration with Ergomed plc

    Sorry forgot to change the heading . This is an interesting new development it appear Allergy Therapeutics has entered into a co-development agreement with Ergomed plc. This ...
    12-Dec-2017
    d gaser
  • Re: Peanut Allergies

    This is an interesting new development it appear Allergy Therapeutics has entered into a co-development agreement with Ergomed plc. Be Happy DAVE 12 December 2017 ...
    12-Dec-2017
    d gaser
  • Peanut Allergies

    Interesting article on p8 of Daily Telegraph today. Year long trial using patches (not injections like AGY). 50% of those wearing the strongest dosage patches experienced a ...
    15-Nov-2017
    jres

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account